Recurrent Breast Cancer


Metastatic Breast Cancer- Ask the Expert, Your Questions Answered (October 11, 2016)

Ask the Expert session with Memorial Sloan Kettering Cancer Center’s Chau T. Dang, MD Dr. Dang discussed advances in the management of metastatic breast cancer and answered your questions in a live... Continue Reading

Breast Cancer Awareness Month: Ask Questions, Get Connected (October 1, 2016)

What does breast cancer awareness month mean to you? We’d like to hear from you—join us on facebook, twitter, or CancerConnect and join the discussion. On October 10th  at 6pm EDT, we will have... Continue Reading

Ribociclib Receives FDA Breakthrough Therapy Designation as First-line Treatment for HR+/HER2- Advanced Breast Cancer (August 3, 2016)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ribociclib (LEE011) in combination with Femara® (letrozole) for the treatment of hormone receptor positive, human... Continue Reading

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (June 22, 2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated... Continue Reading

Adding Carboplatin to Pre-surgery Chemotherapy Improves Survival for Patients with Triple-Negative Breast Cancer (December 22, 2015)

Adding carboplatin to pre-surgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from a German clinical study released at the San... Continue Reading

Adding Carboplatin to Pre-surgery Chemotherapy Improves Survival for Patients with Triple-Negative Breast Cancer (December 21, 2015)

Adding carboplatin to pre-surgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from a German clinical study released at the San... Continue Reading

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk... Continue Reading

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer (October 9, 2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive... Continue Reading

Could Aspirin Treat Breast Cancer? (October 5, 2015)

Researchers from Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) have received a $10 million Breakthrough Award from the Department of Defense’s Office of the Congressionally Directed... Continue Reading

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer (October 1, 2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part... Continue Reading

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths (August 4, 2015)

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered... Continue Reading

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer (March 9, 2015)

CancerConnect News: Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer... Continue Reading

Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer (March 5, 2015)

CancerConnect News:  The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer... Continue Reading

Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer (February 5, 2015)

The combination of Afinitor® (everolimus) plus Herceptin® (trastuzumab) paclitaxel appears effective for patients with advanced HER2-positive breast cancer that is hormone receptor (HR)-negative. These... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included... Continue Reading

Breast Cancer Patients Are Now Living Longer without Relapse (December 18, 2014)

CancerConnect News: Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings... Continue Reading

Neratinib Continues to Show Activity in HER2-Positive Breast Cancer (December 15, 2014)

CancerConnect News: Interim results from an ongoing Phase II clinical trial of neratinib were presented at the 2014 San Antonio Breast Cancer Symposium (SABCS). Neratinib is an investigational, oral medication... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS